Literature DB >> 31356831

Excellence in viral hepatitis elimination - Lessons from Georgia.

Francisco Averhoff1, Jeffrey V Lazarus2, David Sergeenko3, Massimo Colombo4, Amiran Gamkrelidze5, Tengiz Tsertsvadze6, Maia Butsashvili7, David Metreveli8, Lali Sharvadze9, Margaret Hellard10, Stefano Gnes4, Tamar Gabunia3, Muazzam Nasrullah11.   

Abstract

Entities:  

Keywords:  Georgia; Hepatitis C; Hepatitis elimination; Monitoring and evaluation

Mesh：

Year:  2019        PMID： 31356831     DOI： 10.1016/j.jhep.2019.06.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  4 in total

1.  Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.

Authors:  Francisco Averhoff; Shaun Shadaker; Amiran Gamkrelidze; Tatia Kuchuloria; Lia Gvinjilia; Vladimer Getia; David Sergeenko; Maia Butsashvili; Tengiz Tsertsvadze; Lali Sharvadze; Jaba Zarkua; Beth Skaggs; Muazzam Nasrullah
Journal:  J Hepatol       Date:  2019-12-04       Impact factor: 25.083

2.  Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia.

Authors:  Maia Butsashvili; Tinatin Abzianidze; George Kamkamidze; Lasha Gulbiani; Lia Gvinjilia; Tinatin Kuchuloria; Irina Tskhomelidze; Maka Gogia; Maia Tsereteli; Veronique Miollany; Tamar Kikvidze; Shaun Shadaker; Muazzam Nasrullah; Francisco Averhoff
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-03-28

3.  Feasibility and effectiveness of HCV viraemia testing at harm reduction sites in Georgia: A prospective three-arm study.

Authors:  Sonjelle Shilton; Jessica Markby; Maia Japaridze; Violet Chihota; Shaun Shadaker; Lia Gvinjilia; Maia Tsereteli; Maia Alkhazashvili; Maia Butsashvili; Ketevan Stvilia; Ryan Jose Ruiz; Alexander Asatiani; Ekaterine Adamia; Philippa Easterbrook; Irma Khonelidze; Amiran Gamkrelidze
Journal:  Liver Int       Date:  2022-02-18       Impact factor: 8.754

4.  Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.

Authors:  Jisoo A Kwon; Gregory J Dore; Behzad Hajarizadeh; Maryam Alavi; Heather Valerio; Jason Grebely; Rebecca Guy; Richard T Gray
Journal:  PLoS One       Date:  2021-09-16       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.